Prednisolone reduces recurrent wheezing after first rhinovirus wheeze: a 7-year follow-up

Minna Lukkarinen, Heikki Lukkarinen, Pasi Lehtinen, Tytti Vuorinen, Olli Ruuskanen, Tuomas Jartti, Minna Lukkarinen, Heikki Lukkarinen, Pasi Lehtinen, Tytti Vuorinen, Olli Ruuskanen, Tuomas Jartti

Abstract

Background: To better understand the role of human rhinovirus-associated wheeze as a risk factor for childhood recurrent wheezing, a cohort of young children experiencing their first wheezing episode was followed until school age.

Methods: All 111 hospitalized wheezing children (median age, 12 months) were initially participated in a randomized, double-blind, placebo-controlled, parallel trial on the efficacy of oral prednisolone. In this 7-yr follow-up, risk factors for recurrent wheezing were analysed, and then, the efficacy of prednisolone was evaluated overall and in pre-specified subgroups post-hoc. The main outcome was time to recurrent wheezing.

Results: The strongest independent risk factor for recurrent wheezing was rhinovirus detection (hazard ratio 3.54; 95% confidence interval 1.51-8.30) followed by sensitization (3.47; 1.55-8.30, respectively) age <1 yr (2.45; 1.29-4.65) and eczema (2.33; 1.11-4.90). Overall, prednisolone did not prevent recurrent wheezing. In subgroup analysis, prednisolone was associated with less recurrent wheezing in children affected by rhinovirus (0.32; 0.12-0.90, adjusted to sensitization, young age, viral aetiology and parental asthma) and/or with eczema (0.27; 0.08-0.87, adjusted respectively).

Conclusions: Our data strengthen the role of rhinovirus-associated wheeze as an important risk factor for recurrent wheezing and asthma in young first-time wheezing children. Prospective randomized trials on the efficacy of corticosteroids in rhinovirus-associated early wheezing are warranted. (ClinicalTrials.gov number, NCT 00494624).

Trial registration: ClinicalTrials.gov NCT00494624.

© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Risk of recurrent wheezing in prednisolone (bold line) and placebo recipients during a 7‐yr follow‐up. Prednisolone treatment was not associated with overall efficacy in preventing recurrent wheezing, but the treatment was associated with less recurrent wheezing in HRV and/or eczema group. In the HRV‐/RSV‐negative group, there were too few cases in prednisolone recipients with recurrent wheezing (n = 3) for statistical analysis. RSV, respiratory syncytial virus; HRV, human rhinovirus.

References

    1. Kotaniemi‐Syrjänen A, Vainionpää R, Reijonen TM, Waris M, Korhonen K, Korppi M. Rhinovirus‐induced wheezing in infancy–the first sign of childhood asthma? J Allergy Clin Immunol 2003: 111: 66–71.
    1. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high‐risk children. Am J Respir Crit Care Med 2008: 178: 667–672.
    1. Midulla F, Pierangeli A, Cangiano G, et al. Rhinovirus bronchiolitis and recurrent wheezing: one year follow‐up. Eur Respir J 2012: 39: 396–402.
    1. Contoli M, Message SD, Laza‐Stanca V, et al. Role of deficient type III interferon‐lambda production in asthma exacerbations. Nat Med 2006: 12: 1023–1026.
    1. Jartti T, Lehtinen P, Vuorinen T, Ruuskanen O. Bronchiolitis: age and previous wheezing episodes are linked to viral etiology and atopic characteristics. Pediatr Infect Dis J 2009: 28: 311–317.
    1. Jartti T, Kuusipalo H, Vuorinen T, et al. Allergic sensitization is associated with rhinovirus‐, but not other virus‐, induced wheezing in children. Pediatr Allergy Immunol 2010: 21: 1008–1014.
    1. Carroll KN, Gebretsadik T, Minton P, et al. Influence of maternal asthma on the cause and severity of infant acute respiratory tract infections. J Allergy Clin Immunol 2012: 129: 1236–1242.
    1. Jackson DJ, Evans MD, Gangnon RE, et al. Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. Am J Respir Crit Care Med 2012: 185: 281–285.
    1. Kusel MM, Kebadze T, Johnston SL, Holt PG, Sly PD. Febrile respiratory illnesses in infancy and atopy are risk factors for persistent asthma and wheeze. Eur Respir J 2012: 39: 876–882.
    1. Jakiela B, Brockman‐Schneider R, Amineva S, Lee WM, Gern JE. Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection. Am J Respir Cell Mol Biol 2008: 38: 517–523.
    1. Panickar J, Lakhanpaul M, Lambert PC, et al. Oral prednisolone for preschool children with acute virus‐induced wheezing. N Engl J Med 2009: 360: 329–338.
    1. Plint AC, Johnson DW, Patel H, et al. Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med 2009: 360: 2079–2089.
    1. Lehtinen P, Ruohola A, Vanto T, Vuorinen T, Ruuskanen O, Jartti T. Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema. J Allergy Clin Immunol 2007: 119: 570–575.
    1. Allander T, Jartti T, Gupta S, et al. Human bocavirus and acute wheezing in children. Clin Infect Dis 2007: 44: 904–910.
    1. Söderlund‐Venermo M, Lahtinen A, Jartti T, et al. Clinical assessment and improved diagnosis of bocavirus‐induced wheezing in children. Emerg Infect Dis 2009: 15: 1423–1430.
    1. National Asthma Education and Prevention Program . Expert panel report 3 (epr‐3): guidelines for the diagnosis and management of asthma‐summary report 2007. J Allergy Clin Immunol 2007: 120: S94–138.
    1. Matricardi PM, Illi S, Gruber C, et al. Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence. Eur Respir J 2008: 32: 585–592.
    1. Jartti T, Korppi M. Rhinovirus‐induced bronchiolitis and asthma development. Pediatr Allergy Immunol 2011: 22: 350–355.
    1. Sykes A, Edwards MR, Macintyre J, et al. Rhinovirus 16‐induced IFN‐alpha and IFN‐beta are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol 2012: 129(1506–1514): e1506.
    1. Jartti T, Lee WM, Pappas T, Evans M, Lemanske RF Jr, Gern JE. Serial viral infections in infants with recurrent respiratory illnesses. Eur Respir J 2008: 32: 314–320.
    1. van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol 2007: 120: 565–569.
    1. Schuttelaar ML, Kerkhof M, Jonkman MF, et al. Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure. Allergy 2009: 64: 1758–1765.
    1. Illi S, von Mutius E, Lau S, Niggemann B, Gruber C, Wahn U. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet 2006: 368: 763–770.
    1. Jackson DJ, Guilbert TW, Evans MD, et al. Inclusion of Rhinovirus Wheezing History in Early Life Improves the Sensitivity of the Modified Asthma Predictive Index (mAPI). J Allergy Clin Immunol 2009: 123: S82.
    1. Holt PG, Sly PD. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nat Med 2012: 18: 726–735.
    1. Stellato C. Glucocorticoid actions on airway epithelial responses in immunity: functional outcomes and molecular targets. J Allergy Clin Immunol 2007: 120: 1247–1263; quiz 1264‐1245.
    1. de Benedictis FM, Bush A. Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med 2012: 185: 12–23.
    1. Hermanns MI, Unger RE, Kehe K, Peters K, Kirkpatrick CJ. Lung epithelial cell lines in coculture with human pulmonary microvascular endothelial cells: development of an alveolo‐capillary barrier in vitro . Lab Invest 2004: 84: 736–752.
    1. Papi A, Papadopoulos NG, Degitz K, Holgate ST, Johnston SL. Corticosteroids inhibit rhinovirus‐induced intercellular adhesion molecule‐1 up‐regulation and promoter activation on respiratory epithelial cells. J Allergy Clin Immunol 2000: 105: 318–326.
    1. Jartti T, Söderlund‐Venermo M, Hedman K, Ruuskanen O, Mäkelä M. New molecular virus detection methods and their clinical value in lower respiratory tract infections in children. Paediatr Respir Rev 2013: 1: 38–45.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj